{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:12:50Z","timestamp":1788185570590,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":2295,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpsmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pain and Symptom Management"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.jpainsymman.2012.10.230","type":"journal-article","created":{"date-parts":[[2013,2,12]],"date-time":"2013-02-12T20:16:48Z","timestamp":1360700208000},"page":"581-590.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["The Evidence for Pharmacologic Treatment of Neuropathic Cancer Pain: Beneficial and Adverse Effects"],"prefix":"10.1016","volume":"46","author":[{"given":"Joost L.M.","family":"Jongen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark L.","family":"Huijsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jairo","family":"Jessurun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennedy","family":"Ogenio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schipper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan R.C.","family":"Verkouteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Moorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carin C.D.","family":"van der Rijt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris C.","family":"Vissers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpainsymman.2012.10.230_bib1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0304-3959(99)00073-1","article-title":"An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain","volume":"82","author":"Caraceni","year":"1999","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.pain.2011.10.028","article-title":"Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review","volume":"153","author":"Bennett","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0304-3959(89)90012-2","article-title":"Nociceptive nerve pain and neuropathic pain","volume":"39","author":"Vecht","year":"1989","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0304-3959(98)00138-9","article-title":"Assessment and treatment of neuropathic cancer pain following WHO guidelines","volume":"79","author":"Grond","year":"1999","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.pain.2010.06.019","article-title":"The evidence for pharmacological treatment of neuropathic pain","volume":"150","author":"Finnerup","year":"2010","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib6","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1177\/0269216310378546","article-title":"Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review","volume":"25","author":"Bennett","year":"2011","journal-title":"Palliat Med"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib8","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1212\/WNL.0b013e3182166ebe","article-title":"Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation","volume":"76","author":"Bril","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib9","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib11","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/bmj.310.6977.452","article-title":"The number needed to treat: a clinically useful measure of treatment effect","volume":"310","author":"Cook","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib12","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib13","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0885-3924(00)00266-9","article-title":"A\u00a0phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain","volume":"21","author":"Hardy","year":"2001","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0885-3924(01)00373-6","article-title":"Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients","volume":"23","author":"Kannan","year":"2002","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib15","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jpainsymman.2003.09.005","article-title":"Clonazepam as an adjuvant analgesic in patients with cancer-related neuropathic pain","volume":"26","author":"Hugel","year":"2003","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib16","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1089\/jpm.2005.8.1118","article-title":"Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study","volume":"8","author":"Ross","year":"2005","journal-title":"J\u00a0Palliat Med"},{"issue":"Suppl 1","key":"10.1016\/j.jpainsymman.2012.10.230_bib17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000143223","article-title":"Controlled-release oxycodone in the treatment of neuropathic pain of nonmalignant and malignant causes","volume":"74","author":"Ong","year":"2008","journal-title":"Oncology"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib18","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/j.1526-4637.2007.00325.x","article-title":"Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study","volume":"9","author":"Tsavaris","year":"2008","journal-title":"Pain Med"},{"issue":"Suppl","key":"10.1016\/j.jpainsymman.2012.10.230_bib19","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1007\/BF00172630","article-title":"Trazodone for deafferentation pain. Comparison with amitriptyline","volume":"9","author":"Ventafridda","year":"1988","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0304-3959(95)00138-7","article-title":"Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer","volume":"64","author":"Kalso","year":"1996","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/eujp.2001.0266","article-title":"Venlafaxine in neuropathic pain following treatment of breast cancer","volume":"6","author":"Tasmuth","year":"2002","journal-title":"Eur J Pain"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/030089160208800310","article-title":"Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study","volume":"88","author":"Mercadante","year":"2002","journal-title":"Tumori"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jpainsymman.2007.02.043","article-title":"Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms","volume":"35","author":"Kautio","year":"2008","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib24","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1468-1331.2008.02206.x","article-title":"Effect of levetiracetam on the postmastectomy pain syndrome","volume":"15","author":"Vilholm","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/1049909111412539","article-title":"A\u00a0comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study","volume":"29","author":"Mishra","year":"2012","journal-title":"Am J Hosp Palliat Care"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib26","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1200\/JCO.2004.08.141","article-title":"Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group","volume":"22","author":"Caraceni","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib27","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/cncr.23008","article-title":"Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial","volume":"110","author":"Rao","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib28","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1002\/cncr.23482","article-title":"Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial","volume":"112","author":"Rao","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jpainsymman.2006.11.013","article-title":"Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial","volume":"34","author":"Keskinbora","year":"2007","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib30","first-page":"407","article-title":"Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine","volume":"24","author":"Arai","year":"2010","journal-title":"J\u00a0Anesth"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib31","first-page":"80","article-title":"Controlled-release oxycodone alone or combined with gabapentin for management of malignant neuropathic pain","volume":"22","author":"Li","year":"2010","journal-title":"Chin J Canc Res"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib32","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0885-3924(99)00033-0","article-title":"Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain","volume":"17","author":"Caraceni","year":"1999","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib33","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s10147-009-0009-1","article-title":"A\u00a0prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain","volume":"15","author":"Takahashi","year":"2010","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib34","first-page":"2","article-title":"Role of phenytoin in the management of neurogenic cancer pain","volume":"19","author":"Baig","year":"2011","journal-title":"Sri Lankan J Anaesthesiol"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/00044011-200727010-00007","article-title":"Tramadol in the treatment of neuropathic cancer pain: a double-blind, placebo-controlled study","volume":"27","author":"Arbaiza","year":"2007","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1049909108322288","article-title":"Management of neuropathic cancer pain following WHO analgesic ladder: a prospective study","volume":"25","author":"Mishra","year":"2009","journal-title":"Am J Hosp Palliat Care"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib37","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/0959-8049(94)90166-X","article-title":"Medical therapy of malignant nerve pain. A randomised double-blind explanatory trial with naproxen versus slow-release morphine","volume":"30A","author":"Dellemijn","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib38","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0140-6736(88)91218-4","article-title":"Analgesic effects of oral flecainide","volume":"1","author":"Dunlop","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib39","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/0140-6736(91)93019-6","article-title":"Flecainide in cancer nerve pain","volume":"337","author":"Sinnott","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib40","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/0269216307083031","article-title":"Flecainide for the treatment of chronic neuropathic pain: a Phase II trial","volume":"21","author":"von Gunten","year":"2007","journal-title":"Palliat Med"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib41","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1213\/ane.0b013e3181733ddd","article-title":"Ultra-low dose ketamine and memantine treatment for pain in an opioid-tolerant oncology patient","volume":"107","author":"Grande","year":"2008","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib42","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0885-3924(01)00420-1","article-title":"Problems recruiting cancer patients to a comparative clinical trial of drug treatments for neuropathic pain in palliative care","volume":"23","author":"Sinnott","year":"2002","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib43","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2288-2-2","article-title":"Pooling data for number needed to treat: no problems for apples","volume":"2","author":"Moore","year":"2002","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0304-3959(88)90198-4","article-title":"Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain","volume":"33","author":"Arner","year":"1988","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib45","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1212\/WNL.44.5.857","article-title":"Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single-dose studies","volume":"44","author":"Cherny","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.jpainsymman.2012.10.230_bib46","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","article-title":"Neuropathic pain: redefinition and a grading system for clinical and research purposes","volume":"70","author":"Treede","year":"2008","journal-title":"Neurology"},{"issue":"Suppl 2","key":"10.1016\/j.jpainsymman.2012.10.230_bib47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1634\/theoncologist.2009-S501","article-title":"Assessment of cancer-related neuropathy and neuropathic pain","volume":"15","author":"Cleeland","year":"2010","journal-title":"Oncologist"}],"container-title":["Journal of Pain and Symptom Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392412008342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392412008342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:10:37Z","timestamp":1760130637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0885392412008342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0885392412008342"],"URL":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2012.10.230","relation":{},"ISSN":["0885-3924"],"issn-type":[{"value":"0885-3924","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Evidence for Pharmacologic Treatment of Neuropathic Cancer Pain: Beneficial and Adverse Effects","name":"articletitle","label":"Article Title"},{"value":"Journal of Pain and Symptom Management","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2012.10.230","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}